RxDoctor Payments Data

Bhumy Heliker, MD

Urogynecology and Reconstructive Pelvic Surgery · Portland, ORNPI 1770865305

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (54.9%), food and beverage and gifts — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 61.5% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2022 at $1,119 and has fallen 90.6% since, to $105 in 2025.

$2,095in general payments, 2019–2025

Across 31 payments — averaging $67.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$1K
  • Axonics, Inc.$303
  • Boston Scientific$146
  • Medtronic$143
  • Coloplast$130
  • Caldera Medical, Inc$45
  • plus $41 from 2 others

What the payments were for

  • Travel & lodging$1,15055%
  • Food & beverage$92344%
  • Gifts$221%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few urogynecology and reconstructive pelvic surgery providers in Oregonto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$73,835
Medicare patients
126
Services billed
1,302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron83$51,918
GemtesaVibegron69$39,491
Trospium Chloride205$10,813
EstringEstradiol14$7,168
Estradiol114$6,881
Trimethoprim12$955
NitrofurantoinNitrofurantoin Macrocrystal14$611
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst54$539
Clobetasol Propionate16$290
Oxycodone Hcl34$138
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim26$109
Cephalexin12$89

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$15$39,49169 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urogynecology and reconstructive pelvic surgery providers in Oregonon file to place this against a meaningful peer group, so we don't.

Other urogynecology and reconstructive pelvic surgery in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →